Drug Profile
Romosozumab - Amgen/UCB
Alternative Names: AMG-785; Anti-sclerostin; Anti-sclerostin monoclonal antibody; CDP-7851; EVENITY; romosozumab-aqqg; Sclerostin AbLatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator ChiroscienceGroup plc
- Developer Amgen; UCB
- Class Monoclonal antibodies; Osteoporosis therapies
- Mechanism of Action SOST protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Male osteoporosis; Postmenopausal osteoporosis
- Phase III Osteoporosis
- No development reported Osteogenesis imperfecta
- Discontinued Fracture
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Osteogenesis-imperfecta(In adolescents, In children) in Austria (SC, Injection)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Osteogenesis-imperfecta(In adolescents, In children) in Germany (SC, Injection)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Osteogenesis-imperfecta(In adolescents, In children) in Greece (SC, Injection)